PLUS1
1.33
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Stock Name | Stock Symbol | Market | Stock Type |
|---|---|---|---|
| Quince Therapeutics Inc | QNCX | NASDAQ | Common Stock |
| Price Change | Price Change % | Stock Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.33 | 05:02:23 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.33 |
| Trades | Stocks Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.20 - 98.50 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 1.33 | USD |
Period:
Draw Mode:
Quince Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 48.02M | 36.10M | 25.44M | US$ - | US$ - | -3.03 | -0.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | US$ - | - | 382.05k | 6.90% |
Quince Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/16/2022 | 07:00 | Business Wire | Quince Therapeutics Presents Preclinical Data at MHSRS 2022.. |
| 9/12/2022 | 07:00 | Business Wire | Quince Therapeutics Presents Preclinical Data at ASBMR 2022.. |
| 9/08/2022 | 16:59 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/30/2022 | 15:05 | Business Wire | Quince Therapeutics Presents Preclinical Data at OI 2022.. |
| 8/25/2022 | 15:05 | Business Wire | Quince Therapeutics to Present at Upcoming Scientific.. |
| 8/09/2022 | 15:28 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 8/04/2022 | 07:00 | Business Wire | Quince Therapeutics to Present at Canaccord Genuity 42nd.. |
| 8/01/2022 | 08:17 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 7/27/2022 | 07:01 | Business Wire | Cortexyme Corporate Name Change to Quince Therapeutics to.. |
| 7/27/2022 | 07:00 | Business Wire | Cortexyme Successfully Completes Phase 1 Single and Multiple.. |
| 7/22/2022 | 15:26 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 7/08/2022 | 11:57 | Edgar (US Regulatory) | Schedule 13g (sc 13g/a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QNCX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.29 | 1.46 | 1.20 | 1.33 | 173,486 | 0.04 | 3.1% |
| 1 Month | 1.64 | 1.7576 | 1.20 | 1.47 | 215,721 | -0.31 | -18.9% |
| 3 Months | 2.47 | 2.7171 | 1.20 | 1.89 | 248,663 | -1.14 | -46.15% |
| 6 Months | 6.77 | 6.80 | 1.20 | 2.81 | 374,595 | -5.44 | -80.35% |
| 1 Year | 96.23 | 98.50 | 1.20 | 12.14 | 960,829 | -94.90 | -98.62% |
| 3 Years | 22.80 | 121.98 | 1.20 | 23.13 | 443,126 | -21.47 | -94.17% |
| 5 Years | 20.00 | 121.98 | 1.20 | 23.30 | 400,919 | -18.67 | -93.35% |
Quince Therapeutics Description
| Cortexyme Inc is a clinical-stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases. Its approach is based on the seminal discovery of the presence of Porphyromonas gingivalis or P. gingivalis, and its secreted toxic virulence factor proteases called gingipains. The company operates in only one reportable segment that is developing and commercializing therapeutics. |
